Cantor Fitzgerald analyst Pablo Zuanic lowered the firm’s price target on Curaleaf to $12 from $13 and keeps an Overweight rating on the shares after meeting with Chairman Boris Jordan. The analyst sees a challenging 12-18 months for the cannabis sector with no gains on the federal reform front, limited capital access and consumer pressure. For those taking a long-term view, the recent sector selloff generates attractive long-term buying opportunities, writes Zuanic. He sees the biggest and most profitable multistate operators as the "best positioned to benefit in that future disruptive world." Curaleaf should be one of those, contends Zuanic.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CURLF: